IP Library Granted Patent US 9,296,810
Granted Patent B2
US 9,296,810 · App. 12/989,494 · Granted Mar 29, 2016

Fibronectin-based binding molecules and uses thereof

Inventors: John Hastewell (Cambridge, MA); Andreas Loew (Cambridge, MA)
Assignee: NOVARTIS AG
C07K14/78C07K16/005C07K16/18C07K16/2863C07K2317/31C07K2318/20C07K2319/31C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,296,810
App. No.
12/989,494
Granted
Mar 29, 2016
Kind
B2
Abstract

The invention provides fibronectin type III (Fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific Fn3-based binding molecules that bind to two or more targets simultaneously. The Fn3-based binding molecules of the invention can also be linked together to form multispecific Fn3-based binding molecules, and/or can be conjugated to a non-Fn3 moiety, such as, Human Serum Albumin (HSA), for improved half life and stability. The invention also provides methods for generating, screening and using Fn3-based binding molecules in a variety of therapeutic and diagnostic applications.

Claims (1)

1. An Fn3-based binding molecule comprising SEQ ID NO: 120.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2010
From: HASTEWELL, JOHN; LOEW, ANDREAS
To: NOVARTIS AG
Reel/Frame 025478/0068 →
Continuity (2)
Provisional Application 61050142 · May 2, 2008
Related Publication 20110038866A1 · Feb 17, 2011